These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 32322100)

  • 1. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders.
    Ashton NJ; Hye A; Rajkumar AP; Leuzy A; Snowden S; Suárez-Calvet M; Karikari TK; Schöll M; La Joie R; Rabinovici GD; Höglund K; Ballard C; Hortobágyi T; Svenningsson P; Blennow K; Zetterberg H; Aarsland D
    Nat Rev Neurol; 2020 May; 16(5):265-284. PubMed ID: 32322100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg.
    Obrocki P; Khatun A; Ness D; Senkevich K; Hanrieder J; Capraro F; Mattsson N; Andreasson U; Portelius E; Ashton NJ; Blennow K; Schöll M; Paterson RW; Schott JM; Zetterberg H
    Alzheimers Res Ther; 2020 Feb; 12(1):20. PubMed ID: 32111242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
    Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
    J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases.
    Baldacci F; Lista S; O'Bryant SE; Ceravolo R; Toschi N; Hampel H;
    Methods Mol Biol; 2018; 1750():139-155. PubMed ID: 29512070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applying fluid biomarkers to Alzheimer's disease.
    Zetterberg H
    Am J Physiol Cell Physiol; 2017 Jul; 313(1):C3-C10. PubMed ID: 28424166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.
    Lewczuk P; Riederer P; O'Bryant SE; Verbeek MM; Dubois B; Visser PJ; Jellinger KA; Engelborghs S; Ramirez A; Parnetti L; Jack CR; Teunissen CE; Hampel H; Lleó A; Jessen F; Glodzik L; de Leon MJ; Fagan AM; Molinuevo JL; Jansen WJ; Winblad B; Shaw LM; Andreasson U; Otto M; Mollenhauer B; Wiltfang J; Turner MR; Zerr I; Handels R; Thompson AG; Johansson G; Ermann N; Trojanowski JQ; Karaca I; Wagner H; Oeckl P; van Waalwijk van Doorn L; Bjerke M; Kapogiannis D; Kuiperij HB; Farotti L; Li Y; Gordon BA; Epelbaum S; Vos SJB; Klijn CJM; Van Nostrand WE; Minguillon C; Schmitz M; Gallo C; Lopez Mato A; Thibaut F; Lista S; Alcolea D; Zetterberg H; Blennow K; Kornhuber J;
    World J Biol Psychiatry; 2018 Jun; 19(4):244-328. PubMed ID: 29076399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
    JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of proteomics in biomarker discovery in neurodegenerative diseases.
    Davidsson P; Sjögren M
    Dis Markers; 2005; 21(2):81-92. PubMed ID: 15920295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis.
    Wang SY; Chen W; Xu W; Li JQ; Hou XH; Ou YN; Yu JT; Tan L
    J Alzheimers Dis; 2019; 72(4):1353-1361. PubMed ID: 31744001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.
    Mattsson-Carlgren N; Palmqvist S; Blennow K; Hansson O
    Nat Commun; 2020 Dec; 11(1):6252. PubMed ID: 33288742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of biomarkers across different neurodegenerative diseases.
    Ehrenberg AJ; Khatun A; Coomans E; Betts MJ; Capraro F; Thijssen EH; Senkevich K; Bharucha T; Jafarpour M; Young PNE; Jagust W; Carter SF; Lashley T; Grinberg LT; Pereira JB; Mattsson-Carlgren N; Ashton NJ; Hanrieder J; Zetterberg H; Schöll M; Paterson RW
    Alzheimers Res Ther; 2020 May; 12(1):56. PubMed ID: 32404143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?
    Eratne D; Loi SM; Walia N; Farrand S; Li QX; Varghese S; Walterfang M; Evans A; Mocellin R; Dhiman K; Gupta V; Malpas CB; Collins S; Masters CL; Velakoulis D
    Aust N Z J Psychiatry; 2020 Jan; 54(1):57-67. PubMed ID: 31220922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist.
    Alcolea D; Beeri MS; Rojas JC; Gardner RC; Lleó A
    Neurology; 2023 Jul; 101(4):172-180. PubMed ID: 36878698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
    Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
    J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment.
    Gonzalez-Cuyar LF; Sonnen JA; Montine KS; Keene CD; Montine TJ
    Curr Neurol Neurosci Rep; 2011 Oct; 11(5):455-63. PubMed ID: 21725901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up.
    Bruzova M; Rusina R; Stejskalova Z; Matej R
    Sci Rep; 2021 May; 11(1):10837. PubMed ID: 34035398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How many biomarkers to discriminate neurodegenerative dementia?
    Sancesario GM; Bernardini S
    Crit Rev Clin Lab Sci; 2015; 52(6):314-26. PubMed ID: 26292074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases.
    Campese N; Palermo G; Del Gamba C; Beatino MF; Galgani A; Belli E; Del Prete E; Della Vecchia A; Vergallo A; Siciliano G; Ceravolo R; Hampel H; Baldacci F
    Expert Rev Proteomics; 2021 Jan; 18(1):27-48. PubMed ID: 33545008
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.